{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vision+Disorder&page=8",
    "query": {
      "condition": "Vision Disorder",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 2082,
    "total_pages": 209,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vision+Disorder&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vision+Disorder&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T08:19:59.351Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01835145",
      "title": "Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Uveal Melanoma",
        "Stage III Uveal Melanoma AJCC v7",
        "Stage IIIA Uveal Melanoma AJCC v7",
        "Stage IIIB Uveal Melanoma AJCC v7",
        "Stage IIIC Uveal Melanoma AJCC v7",
        "Stage IV Uveal Melanoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2013-07-31",
      "completion_date": "2019-11-01",
      "has_results": true,
      "last_update_posted_date": "2022-08-04",
      "last_synced_at": "2026-10-29T08:19:59.351Z",
      "location_count": 224,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Burbank, California + 141 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01835145"
    },
    {
      "nct_id": "NCT00691639",
      "title": "Collection of Blood Specimens From Patients in AL-3789 Studies for Elevated Intraocular Pressure (IOP)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Open-Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Blood Collection Only",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2008-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-10-01",
      "last_synced_at": "2026-10-29T08:19:59.351Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00691639"
    },
    {
      "nct_id": "NCT01864642",
      "title": "Effects of a Single OMT on Intraocular Pressure (IOP) in Ocular Hypertenive or Glaucoma Suspect Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "osteopathic manipulative treatment (OMT)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 28,
      "start_date": "2013-07",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-08-18",
      "last_synced_at": "2026-10-29T08:19:59.351Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01864642"
    },
    {
      "nct_id": "NCT04140279",
      "title": "A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Latanoprostene Bunod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-05-13",
      "completion_date": "2023-08",
      "has_results": false,
      "last_update_posted_date": "2024-03-04",
      "last_synced_at": "2026-10-29T08:19:59.351Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04140279"
    },
    {
      "nct_id": "NCT05656027",
      "title": "Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Presbyopia",
        "Refractive Error",
        "Eye Diseases",
        "Near Vision"
      ],
      "interventions": [
        {
          "name": "Aceclidine+Brimonidine combination ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Aceclidine ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LENZ Therapeutics, Inc",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "45 Years to 75 Years"
      },
      "enrollment_count": 469,
      "start_date": "2022-12-19",
      "completion_date": "2024-01-25",
      "has_results": true,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-10-29T08:19:59.351Z",
      "location_count": 25,
      "location_summary": "Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 20 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05656027"
    },
    {
      "nct_id": "NCT07048886",
      "title": "Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Primary Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Rocklatan (netarsudil 0.02% and latanoprost 0.005%)",
          "type": "DRUG"
        },
        {
          "name": "Systane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Center for Sight Las Vegas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2025-07-15",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-07-03",
      "last_synced_at": "2026-10-29T08:19:59.351Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07048886"
    },
    {
      "nct_id": "NCT03862053",
      "title": "Manuka Eye Droops for Treatment of Allergy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Manuka honey",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Toyos Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 0,
      "start_date": "2020-01-01",
      "completion_date": "2020-10-07",
      "has_results": false,
      "last_update_posted_date": "2020-10-09",
      "last_synced_at": "2026-10-29T08:19:59.351Z",
      "location_count": 2,
      "location_summary": "Germantown, Tennessee • Nashville, Tennessee",
      "locations": [
        {
          "city": "Germantown",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03862053"
    },
    {
      "nct_id": "NCT01254370",
      "title": "Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension",
        "Ocular Surface Disease"
      ],
      "interventions": [
        {
          "name": "Latanoprost",
          "type": "DRUG"
        },
        {
          "name": "Travatan Z",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen SAS",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 105,
      "start_date": "2010-11",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2016-06-06",
      "last_synced_at": "2026-10-29T08:19:59.351Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01254370"
    },
    {
      "nct_id": "NCT07465289",
      "title": "A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ocular Myasthenia Gravis"
      ],
      "interventions": [
        {
          "name": "Rozanolixizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2026-09-16",
      "completion_date": "2031-03-17",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-10-29T08:19:59.351Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07465289"
    },
    {
      "nct_id": "NCT07348276",
      "title": "First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Progressive Supranuclear Palsy (PSP)",
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "[18F]ABBV-964i",
          "type": "DRUG"
        },
        {
          "name": "[18F]ABBV-965i",
          "type": "DRUG"
        },
        {
          "name": "Lead Candidate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Invicro",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 11,
      "start_date": "2025-11-17",
      "completion_date": "2026-03-23",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-29T08:19:59.351Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07348276"
    }
  ]
}